Idioma:

Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study

Feres, Fausto, MD, PhD ; Costa, Ricardo A., MD, PhD ; Bhatt, Deepak L., MD, MPH ; Leon, Martin B., MD ; Botelho, Roberto V., MD, PhD ; King, Spencer B., MD ; de Paula, J. Eduardo T., MD ; Mangione, José A., MD, PhD ; Salvadori, Décio, MD ; Gusmão, Marcos O., MD ; Castello, Hélio, MD, MSc ; Nicolela, Eduardo, MD ; Perin, Marco A., MD, PhD ; Devito, Fernando S., MD, PhD ; Marin-Neto, J. Antônio, MD, PhD ; Abizaid, Alexandre, MD, PhD

The American heart journal, 2012-12, Vol.164 (6), p.810-816.e3 [Periódico revisado por pares]

New York, NY: Mosby, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study
Autor: Feres, Fausto, MD, PhD ; Costa, Ricardo A., MD, PhD ; Bhatt, Deepak L., MD, MPH ; Leon, Martin B., MD ; Botelho, Roberto V., MD, PhD ; King, Spencer B., MD ; de Paula, J. Eduardo T., MD ; Mangione, José A., MD, PhD ; Salvadori, Décio, MD ; Gusmão, Marcos O., MD ; Castello, Hélio, MD, MSc ; Nicolela, Eduardo, MD ; Perin, Marco A., MD, PhD ; Devito, Fernando S., MD, PhD ; Marin-Neto, J. Antônio, MD, PhD ; Abizaid, Alexandre, MD, PhD
Assuntos: Adult ; Aspirin - adverse effects ; Aspirin - therapeutic use ; Biological and medical sciences ; Brazil ; Cardiology. Vascular system ; Cardiovascular ; Clinical outcomes ; Coronary Angiography ; Coronary Artery Disease - complications ; Coronary Artery Disease - mortality ; Coronary Artery Disease - therapy ; Drug therapy ; Drug Therapy, Combination ; Drug-Eluting Stents ; Heart attacks ; Humans ; Medical sciences ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Postoperative Period ; Prospective Studies ; Research Design ; Sirolimus - administration & dosage ; Sirolimus - analogs & derivatives ; Stents ; Studies ; Ticlopidine - adverse effects ; Ticlopidine - analogs & derivatives ; Ticlopidine - therapeutic use ; Time Factors ; Treatment Outcome ; Young Adult
É parte de: The American heart journal, 2012-12, Vol.164 (6), p.810-816.e3
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Descrição: Background Current recommendations for antithrombotic therapy after drug-eluting stent (DES) implantation include prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel ≥12 months. However, the impact of such a regimen for all patients receiving any DES system remains unclear based on scientific evidence available to date. Also, several other shortcomings have been identified with prolonged DAPT, including bleeding complications, compliance, and cost. The second-generation Endeavor zotarolimus-eluting stent (E-ZES) has demonstrated efficacy and safety, despite short duration DAPT (3 months) in the majority of studies. Still, the safety and clinical impact of short-term DAPT with E-ZES in the real world is yet to be determined. Methods The OPTIMIZE trial is a large, prospective, multicenter, randomized (1:1) non-inferiority clinical evaluation of short-term (3 months) vs long-term (12-months) DAPT in patients undergoing E-ZES implantation in daily clinical practice. Overall, 3,120 patients were enrolled at 33 clinical sites in Brazil. The primary composite endpoint is death (any cause), myocardial infarction, cerebral vascular accident, and major bleeding at 12-month clinical follow-up post-index procedure. Conclusions The OPTIMIZE clinical trial will determine the clinical implications of DAPT duration with the second generation E-ZES in real-world patients undergoing percutaneous coronary intervention.
Editor: New York, NY: Mosby, Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Resultado 1 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study

New York, NY: Mosby, Inc

Buscando em bases de dados remotas. Favor aguardar.